Thermo Fisher Scientific and Symphogen, antibody centre of excellence within Servier, have announced the continuation of their collaboration to provide biopharmaceutical discovery and development laboratories with tools and workflows for the characterisation of complex therapeutic proteins.
Since the collaboration began in 2018, Symphogen has adopted updated instruments and software aimed to improve data quality and processes to develop, test and routinely implement platform workflows for intact and native mass analysis of therapeutic monoclonal antibody mixtures. Most recently, the implementation of Thermo Fisher’s Orbitrap Exploris MX Mass Detector enables higher data confidence and a more efficient workflow. The system adds to Symphogen’s range of Thermo Fisher high-resolution accurate mass (HRAM) mass spectrometry technologies, which are controlled using the company’s Chromeleon Chromatography Data System (CDS) software, allowing secure, remote operations and data processing from anywhere in the world.
"The extension of our collaborative relationship with Symphogen demonstrates our continued commitment to solve tangible scientific challenges within the biopharmaceutical industry," said Eric Grumbach, Director Biopharma, Pharma Business, Chromatography And Mass Spectrometry, Thermo Fisher. "Further investment in this collaboration enables critical insights that feed directly into the development of new analytical tools, providing meaningful impact to the characterization of complex biotherapeutics."
Dan Bach Kristensen, Principal Investigator, Symphogen, said, "Mass spectrometry is playing an increasingly important role in biopharmaceutical development at Symphogen, as exemplified in 2021, when we analysed over 10,000 biopharmaceutical samples by intact mass analysis on our Orbitrap mass spectrometers. A multitude of separation techniques are now routinely hyphenated to our mass spectrometers, providing unrivalled insight into product quality, from early discovery to late-stage clinical development."